NCT04939363View on ClinicalTrials.gov

A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome;

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 8, 2021

Primary Completion Date

October 9, 2024

Study Completion Date

December 4, 2024

Conditions
Richter's Syndrome
Interventions
COMBINATION_PRODUCT

Obinutuzumab with Ibrutinib and Venetoclax

"1. Obinutuzumab intravenous infusion:~2. Ibrutinib PO 560mg daily starting on cycle 1 day 1 for 12 cycles.~3. Venetoclax with an accelerated ramp-up and close inpatient Tumor Lysis Syndromes (TLS) monitoring starts on cycle 1 day 15 to the target dose of 400mg daily for a total of 12 cycles:"

Trial Locations (4)

Unknown

Bnai Zion Medical Center, Haifa

Hadassah Medical Center, Jerusalem

TASMC, Tel Aviv

Sheba Medical Center, Tel Litwinsky

Sponsors
All Listed Sponsors
collaborator

Tel-Aviv Sourasky Medical Center

OTHER_GOV

lead

Bnai Zion Medical Center

OTHER_GOV

NCT04939363 - A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome; | Biotech Hunter | Biotech Hunter